Engineered immune cells take on advanced cancers in early trial

This early-phase study tests a new treatment called GC203 TIL for people with advanced solid tumors (cancers in organs like the breast, lung, or gut) that have not responded to standard therapies. The treatment uses a patient's own immune cells, which are modified in a lab to better attack cancer cells, then infused back. The main goals are to find the safest dose and check for side effects, while also measuring if tumors shrink. Only 18 adults aged 18-75 will take part.